Open AccessThis article is
- freely available
Antibody Drug Conjugates as Cancer Therapeutics
Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA
Received: 24 December 2012; in revised form: 11 February 2013 / Accepted: 18 February 2013 / Published: 27 February 2013
Abstract: Monoclonal antibody (MAb) based therapies have achieved considerable success in oncology, primarily when used in combination with cytotoxic drugs. Antibody drug conjugates (ADCs) are a class of therapeutics that harness the antigen-selectivity of MAbs to deliver highly potent cytotoxic drugs to antigen-expressing tumor cells. The use of MAb directed delivery can confer a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Although simple in concept, to achieve the design goal of improved therapeutic efficacy and reduced toxicity, each of the components of an ADC; the MAb, linker and drug need to considered in the context of the targeted antigen, the selectivity of antigen expression and the biology of the tumor type on which the target antigen is expressed. The characteristics of targets, MAbs, linkers and drugs being used in ADC design are discussed.
Keywords: antibody drug conjugate; ADC; immunoconjugate; antibody; cytotoxic; cancer; drug delivery
Citations to this Article
Cite This Article
MDPI and ACS Style
Trail, P.A. Antibody Drug Conjugates as Cancer Therapeutics. Antibodies 2013, 2, 113-129.
Trail PA. Antibody Drug Conjugates as Cancer Therapeutics. Antibodies. 2013; 2(1):113-129.
Trail, Pamela A. 2013. "Antibody Drug Conjugates as Cancer Therapeutics." Antibodies 2, no. 1: 113-129.